Sequent Scientific
SEQUENT
Sequent Scientific Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 2,78,964 |
| Weekly | 3.59% | 70,26,640 |
| Monthly | 22.29% | 5,30,18,488 |
Sequent Scientific Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| SEQUENT | - | 3.59% | 22.29% |
| Index | - | - | - |
| Peer Avg. | - | 5.43% | 11.51% |
Sequent Scientific Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| SEQUENT | 152.57 | 4.25 | 29.46 | 4.03 | 4.36 | - |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Sequent Scientific Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | -6.75% | -55.39% | 4.03% | 4.36% |
| FY '20-21 | 16.12% | 38.89% | 9.19% | 10.35% |
| FY '19-20 | 25.10% | 112.79% | 7.23% | 7.77% |
Sequent Scientific Shareholding Pattern
Sequent Scientific Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 816.22 | 767.51 | 73.57 | 29.93 |
| FY '20-21 | 813.54 | 696.59 | 137.84 | 68.28 |
| FY '19-20 | 703.29 | 607.01 | 108.60 | 51.69 |
Sequent Scientific Share Price
SeQuent Scientific Limited is an integrated pharmaceutical company operating in India. The company operates in the field of animal health, where it offers active pharmaceutical ingredients (API) and usable dosage forms, as well as analytical services. The company offers application interfaces and formulations through its subsidiary Alivira Animal Health Limited. Alivira Animal Health Limited has manufacturing facilities in five countries including India. The company's subsidiary, Sequent Research Limited, is a contract research organisation providing analytical and bioanalytical services to support companies in the API, pharmaceutical, personal care and nutrition industries. Sequent Research Limited provides complete analytical solutions including method validation, stability, microbiology of APIs and finished products in a wide range of dosage forms according to pharmacopoeia monographs, customer developed methods or in-house.